TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02076087

Intervention type: PROCEDURE
Intervention: Liposuction/lipectomy
Description: Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells

Intervention type: PROCEDURE
Intervention: Liposuction/lipectomy
Description: Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells

Intervention type: PROCEDURE
Intervention: Liposuction/lipectomy
Description: Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
Study: NCT04146012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artegraft® Collagen Vascular Graft™ (Artegraft)
Description: The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artegraft® Collagen Vascular Graft™ (Artegraft)
Description: The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
Study: NCT01050439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UDAlloSCT
Description: unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
Study: NCT02474277

Intervention type: OTHER
Group type: OTHER
Intervention: 30 sec chair stand test
Description: diagnostic test for functional impairment
Study: NCT03507088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroestradiol (18F)
Description: A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
Study: NCT00939211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03068741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison 1: Prehospital Ceftriaxone
Description: Paramedics will administer 1g of intramuscular ceftriaxone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparison 1: Placebo
Description: Paramedics will administer an identical volume of reconstituted intramuscular placebo.
Study: NCT03042884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Exercise Tracker Watch
Description: Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Exercise Tracker Watch
Description: Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit.
Study: NCT00727155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusting to Chronic Conditions Using Education Support and Skills
Description: This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
Study: NCT05370105

Intervention type: OTHER
Intervention: blood withdrawal
Description: 10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies.

Intervention type: OTHER
Intervention: blood withdrawal
Description: 10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies.
Study: NCT00767403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention + Stepped Care
Description: Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Intervention
Description: As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Website
Description: Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
Study: NCT00748761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Contact waitlist weekly for 12 weeks
Study: NCT00795327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra (Poly-L-Lactic Acid Dermal Implant)
Description: Drug Device study
Study: NCT00511732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Technosphere Insulin Inhalation Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Placebo
Description: Technosphere Inhalation Powder
Study: NCT04168892

Intervention type: DRUG
Intervention: 150 IU of HMG in patients with age ≤ 35 years
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.

Intervention type: DRUG
Intervention: 225 IU of HMG in patients with age > 35 years
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
Study: NCT00886509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: s.c. administration of pegylated G-CSF over 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: s.c. administration of pegylated G-CSF over 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control Arm 1: Collateral promotion; PCI after 6 months
Study: NCT06383455

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal therapy
Description: An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal therapy
Description: An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
Study: NCT02690038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Description: Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization
Study: NCT00307398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Description: One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
Study: NCT00356525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
Study: NCT01196416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study: NCT02823379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: A Smartphone delivered physical activity program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
Study: NCT03507010

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Radiotherapy
Description: Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
Study: NCT03202134

Intervention type: OTHER
Intervention: opioid free anesthesia
Description: general anesthesia blocking reflexes without using an opioid
Study: NCT00315016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: active comparator
Study: NCT03825848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans jugular intrahepatic portal systemic shunt
Description: Shunting left or right PV branch in the TIPS procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans jugular intrahepatic portal systemic shunt
Description: Shunting left or right PV branch in the TIPS procedure
Study: NCT04491591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction Education and Support Tool (BREASTChoice)
Description: The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Website
Description: -(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Survey
Description: -Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
Study: NCT04391192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Overdose Response
Description: All participants will be provided the phone number and encouraged to call when they use alone.
Study: NCT04372121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study: NCT01784081

Intervention type: OTHER
Intervention: Palliative care with decision aids
Description: Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
Study: NCT01526343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal XT implantation
Description: The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
Study: NCT01682343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk-calcium supplement
Study: NCT00719706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetyl-l-carnitine PLUS alpha-lipoic acide
Description: 1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04914650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
Study: NCT02131142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom drug coated coronary stent
Description: Placement of a BioFreedom drug coated stent in a narrow coronary artery
Study: NCT02691845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BA (brief advice)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA (brief advice)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BA (brief advice)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE (supervised and home-based exercise)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHE (supervised and home-based exercise)
Study: NCT00356525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
Study: NCT01656980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tumor resection surgery
Description: For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
Study: NCT02848209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCA 20% Peeling
Description: TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phenol/croton oil Peeling
Description: Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCA 40% Peeling
Description: TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
Study: NCT04177407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
Description: Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
Study: NCT03639779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: A volume of 0.1 ml/cm2 of STS will be injected into each lesion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
Study: NCT03633825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief help-seeking barrier reduction intervention
Description: The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.